Selective inhibition of angiotensin receptor signaling through Erk1/2 pathway by a novel peptide

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 306, Issue 8, 2014, Pages

  Liu, Jun ^a   Yosten, Gina L C ^b   Ji, Hong ^a   Zhang, Dan ^a   Zheng, Wei ^a   Speth, Robert C ^c   Samson, Willis K ^b   Sandberg, Kathryn ^a,d  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Angiotensin II; Angiotensin receptor; Erk1 2; PEP7; Sodium intake

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXYTOCIN ANTAGONIST; PEP7 PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CELL CULTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXON; FEMALE; FLUID INTAKE; HUMAN; HUMAN CELL; LIVER MEMBRANE; MALE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ERK1/2; PEP7; SODIUM INTAKE;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DRINKING; FEMALE; HYPERTENSION; MALE; MAP KINASE SIGNALING SYSTEM; OLIGOPEPTIDES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN;

EID: 84900545000     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00562.2013     Document Type: Article

References (40)

1. Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hubinger G, Kieff E, Herrmann F, Leutz A, Gruss HJ. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 93: 14053-14058, 1996.
2. Aplin M, Bonde MM, Hansen JL. Molecular determinants of angiotensin II type 1 receptor functional selectivity. J Mol Cell Cardiol 46: 15-24, 2009.
3. Blackburn RE, Samson WK, Fulton RJ, Stricker EM, Verbalis JG. Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite in rats. Am J Physiol Regul Integr Comp Physiol 269: R245-R251, 1995.
4. Blackburn RE, Samson WK, Fulton RJ, Stricker EM, Verbalis JG. Central oxytocin inhibition of salt appetite in rats: evidence for differential sensing of plasma sodium and osmolality. Proc Natl Acad Sci USA 90: 10380-10384, 1993.
5. Blackburn RE, Demko AD, Hoffman GE, Stricker EM, Verbalis JG. Central oxytocin inhibition of angiotensin-induced salt appetite in rats. Am J Physiol Regul Integr Comp Physiol 263: R1347-R1353, 1992.
6. Bonde MM, Hansen JT, Sanni SJ, Haunso S, Gammeltoft S, Lyngso C, Hansen JL. Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms. PLoS One 5: e14135, 2010.
7. Buggy J, Johnson AK. Angiotensin-induced thirst: effects of third ventricle obstruction and periventricular ablation. Brain Res 149: 117-128, 1978.
8. Choudhury D, Levi M. Kidney aging-inevitable or preventable? Nat Rev Nephrol 7: 706-717, 2011.
9. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003, 2002.
10. Daniels D, Mietlicki EG, Nowak EL, Fluharty SJ. Angiotensin II stimulates water and NaCl intake through separate cell signalling pathways in rats. Exp Physiol 94: 130-137, 2009.
11. Daniels D, Yee DK, Faulconbridge LF, Fluharty SJ. Divergent behavioral roles of angiotensin receptor intracellular signaling cascades. Endocrinology 146: 5552-5560, 2005.
12. Daniels D, Yee DK, Fluharty SJ. Angiotensin II receptor signalling. Exp Physiol 92: 523-527, 2007.
13. Doan TN, Ali MS, Bernstein KE. Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling. J Biol Chem 276: 20954-20958, 2001.
14. Felgendreger LA, Fluharty SJ, Yee DK, Flanagan-Cato LM. Endogenous angiotensin II-induced p44/42 mitogen-activated protein kinase activation mediates sodium appetite but not thirst or neurohypophysial secretion in male rats. J Neuroendocrinol 25: 97-106, 2013.
15. Filmore D. It's a GPCR world. Modern Drug Discovery 7: 24-29, 2004.
16. Godin CM, Ferguson SS. Biased agonism of the angiotensin II type 1 receptor. Mini Rev Med Chem 12: 812-816, 2012.
17. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, Thomas WG. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 61: 768-777, 2002.
18. Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194: 495-496, 1962.
19. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 20: 953-970, 2006.
20. Inagami T, Eguchi S, Numaguchi K, Motley ED, Tang H, Matsumoto T, Yamakawa T. Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. J Am Soc Nephrol 10 Suppl 11: S57-S61, 1999.
21. Ji H, Zhang Y, Zheng W, Wu Z, Lee S, Sandberg K. Translational regulation of angiotensin type 1a receptor expression and signaling by upstream AUGs in the 5′ leader sequence. J Biol Chem 279: 45322-45328, 2004.
22. Ji H, Zheng W, Falconetti C, Roesch DM, Mulroney SE, Sandberg K. 17-estradiol deficiency reduces potassium excretion in an angiotensin type 1 receptor-dependent manner. Am J Physiol Heart Circ Physiol 293: H17-H22, 2007.
23. Jones DW, Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 43: 1-3, 2004.
24. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 196: 947-950, 1987.
25. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 338: b1665, 2009.
26. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′ leader cistron of the human 2-adrenergic receptor regulate receptor expression. J Clin Invest 102: 1927-1932, 1998.
27. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-C97, 2007.
28. Murphy BP, Stanton T, Dunn FG. Hypertension and myocardial ischemia. Med Clin North Am 93: 681-695, 2009.
29. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275: 17201-17210, 2000.
30. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 5: 993-996, 2006.
31. Rabadan-Diehl C, Martinez A, Volpi S, Subburaju S, Aguilera G. Inhibition of vasopressin V1b receptor translation by upstream open reading frames in the 5′-untranslated region. J Neuroendocrinol 19: 309-319, 2007.
32. Rhee SG, Choi KD. Regulation of inositol phospholipid-specific phospholipase C isozymes. J Biol Chem 267: 12393-12396, 1992.
33. Rogers JL, Mitchell AR, Maric C, Sandberg K, Myers A, Mulroney SE. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am J Physiol Regul Integr Comp Physiol 292: R794-R799, 2007.
34. Simpson JB, Epstein AN, Camardo JS Jr. Localization of receptors for the dipsogenic action of angiotensin II in the subfornical organ of rat. J Comp Physiol Psychol 92: 581-601, 1978.
35. Speth RC. Sarcosine1, glycine8 angiotensin II is an AT1 angiotensin II receptor subtype selective antagonist. Regul Pept 115: 203-209, 2003.
36. Wang M, Monticone RE, Lakatta EG. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens 19: 201-207, 2010.
37. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100: 10782-10787, 2003.
38. Yee DK, Suzuki A, Luo L, Fluharty SJ. Identification of structural determinants for G protein-independent activation of mitogen-activated protein kinases in the seventh transmembrane domain of the angiotensin II type 1 receptor. Mol Endocrinol 20: 1924-1934, 2006.
39. Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol 298: R1642-R1647, 2010.
40. Zimmer A, Zimmer AM, Reynolds K. Tissue specific expression of the retinoic acid receptor-β2: regulation by short open reading frames in the 5′-noncoding region. J Cell Biol 127: 1111-1119, 1994.